(Q42595705)

3 November 2017

Survival in patients with pulmonary arterial hypertension treated with first-line bosentan (English)

1 reference

3 November 2017

arterial hypertension

1 reference

V V McLaughlin

1

1 reference

3 November 2017

1 September 2006

1 reference

European Journal of Clinical Investigation

3 November 2017

1 reference

3 November 2017

36 Suppl 3

1 reference

3 November 2017

10-15

1 reference

Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines

3 November 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2006.01688.X

Beraprost therapy for pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2006.01688.X

Clinical efficacy and survival with first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2006.01688.X

End points and clinical trial designs in pulmonary arterial hypertension: clinical and regulatory perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2006.01688.X

Effectiveness of a nonselective ET(A/B) and a selective ET(A) antagonist in rats with monocrotaline-induced pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2006.01688.X

Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2006.01688.X

Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and doppler measures in patients with pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2006.01688.X

Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2006.01688.X

Survival with first-line bosentan in patients with primary pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2006.01688.X

Survival in patients with primary pulmonary hypertension. Results from a national prospective registry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2006.01688.X

Survival in primary pulmonary hypertension. Validation of a prognostic equation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2006.01688.X

Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2006.01688.X

Pulmonary arterial hypertension: the race for the most effective treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2006.01688.X

Vasodilator therapy for primary pulmonary hypertension in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2006.01688.X

Outcomes in children with idiopathic pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2006.01688.X

Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2006.01688.X

Survival in primary pulmonary hypertension: the impact of epoprostenol therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2006.01688.X

Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2006.01688.X

Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2006.01688.X

A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2006.01688.X

Prostanoid therapy for pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2006.01688.X

Improving survival in pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2006.01688.X

Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2006.01688.X

Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2006.01688.X

Combination therapy for pulmonary arterial hypertension: still more questions than answers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2006.01688.X

Long-Term Treatment of Primary Pulmonary Hypertension with Aerosolized Iloprost, a Prostacyclin Analogue

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2006.01688.X

10.1111/J.1365-2362.2006.01688.X

21 January 2018

Identifiers

DOI

1 reference

release_kdnrnupglfejhl6cu4kvgft22q

3 November 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/kdnrnupglfejhl6cu4kvgft22q

mapped directly with Wikidata item

24 November 2022

based on heuristic

PubMed ID

16919005

1 reference

PubMed ID

16919005